BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bosch-Barrera J, Menendez JA. Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treat Rev. 2015;41:540-546. [PMID: 25944486 DOI: 10.1016/j.ctrv.2015.04.008] [Cited by in Crossref: 95] [Cited by in F6Publishing: 100] [Article Influence: 13.6] [Reference Citation Analysis]
Number Citing Articles
1 Shao G, Liu Y, Lu L, Zhang G, Zhou W, Wu T, Wang L, Xu H, Ji G. The Pathogenesis of HCC Driven by NASH and the Preventive and Therapeutic Effects of Natural Products. Front Pharmacol 2022;13:944088. [DOI: 10.3389/fphar.2022.944088] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hua Y, Yuan X, Shen Y, Wang J, Azeem W, Yang S, Gade A, Lellahi SM, Øyan AM, Ke X, Zhang W, Kalland K. Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain. Front Pharmacol 2022;13:836724. [DOI: 10.3389/fphar.2022.836724] [Reference Citation Analysis]
3 Qi Q, Sun Y, Yang Y, Liu Y. Circ_0000274 contributes to renal cell carcinoma progression by regulating miR-338-3p/NUCB2 axis and JAK1/STAT3 pathway. Transplant Immunology 2022. [DOI: 10.1016/j.trim.2022.101626] [Reference Citation Analysis]
4 Javeed A, Ahmed M, Sajid AR, Sikandar A, Aslam M, Hassan TU, Samiullah, Nazir Z, Ji M, Li C. Comparative Assessment of Phytoconstituents, Antioxidant Activity and Chemical Analysis of Different Parts of Milk Thistle Silybum marianum L. Molecules 2022;27:2641. [PMID: 35565993 DOI: 10.3390/molecules27092641] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Bai Y, Chen J, Hu W, Wang L, Wu Y, Yu S. Silibinin Therapy Improves Cholangiocarcinoma Outcomes by Regulating ERK/Mitochondrial Pathway. Front Pharmacol 2022;13:847905. [DOI: 10.3389/fphar.2022.847905] [Reference Citation Analysis]
6 Chi M, Zhang H, Wang Y, Sun X, Yang Q, Guo C, Sakuma K. Silibinin Alleviates Muscle Atrophy Caused by Oxidative Stress Induced by Cisplatin through ERK/FoxO and JNK/FoxO Pathways. Oxidative Medicine and Cellular Longevity 2022;2022:1-22. [DOI: 10.1155/2022/5694223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Devkota HP. Nutraceutical Compounds, Classification, Biosynthesis, and Function. Nutraceuticals Production from Plant Cell Factory 2022. [DOI: 10.1007/978-981-16-8858-4_1] [Reference Citation Analysis]
8 Bosch-Barrera J, Roqué A, Teixidor E, Carmona-Garcia MC, Arbusà A, Brunet J, Martin-Castillo B, Cuyàs E, Verdura S, Menendez JA. Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals (Basel) 2021;15:19. [PMID: 35056076 DOI: 10.3390/ph15010019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Baksi R, Rana R, Nivsarkar M. Chemopreventive potential of plant-derived epigenetic inhibitors silibinin and quercetin: an involvement of apoptotic signaling cascade modulation. Futur J Pharm Sci 2021;7:69. [DOI: 10.1186/s43094-021-00214-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Никольский А, Шиловский И, Барвинская Е, Корнеев А, Сундукова М, Хаитов М. Роль транскрипционного фактора STAT3 в патогенезе бронхиальной астмы. БМ 2021;86:1654-1667. [DOI: 10.31857/s032097252111004x] [Reference Citation Analysis]
11 Nikolskii AA, Shilovskiy IP, Barvinskaia ED, Korneev AV, Sundukova MS, Khaitov MR. Role of STAT3 Transcription Factor in Pathogenesis of Bronchial Asthma. Biochemistry Moscow 2021;86:1489-1501. [DOI: 10.1134/s0006297921110122] [Reference Citation Analysis]
12 Tobeiha M, Rajabi A, Raisi A, Mohajeri M, Yazdi SM, Davoodvandi A, Aslanbeigi F, Vaziri M, Hamblin MR, Mirzaei H. Potential of natural products in osteosarcoma treatment: Focus on molecular mechanisms. Biomed Pharmacother 2021;144:112257. [PMID: 34688081 DOI: 10.1016/j.biopha.2021.112257] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Addeo R. Silibinin: A New Opportunity for the Treatment of Brain Metastasis from Lung Cancer. J Exp Pharmacol 2021;13:901-3. [PMID: 34611448 DOI: 10.2147/JEP.S326871] [Reference Citation Analysis]
14 Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA. Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers (Basel) 2021;13:4168. [PMID: 34439322 DOI: 10.3390/cancers13164168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
15 Qi YS, Xie JB, Xie P, Duan Y, Ling YQ, Gu YL, Piao XL. Uncovering the anti-NSCLC effects and mechanisms of gypenosides by metabolomics and network pharmacology analysis. J Ethnopharmacol 2021;281:114506. [PMID: 34371113 DOI: 10.1016/j.jep.2021.114506] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
16 Chavoshy F, Zadeh BSM, Tamaddon AM, Anbardar MH. Delivery and Anti-Psoriatic Effect of Silibinin-Loaded Polymeric Micelles: An Experimental Study in the Psoriatic Skin Model. Curr Drug Deliv 2020;17:787-98. [PMID: 32703129 DOI: 10.2174/1567201817666200722141807] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
17 Man S, Luo C, Yan M, Zhao G, Ma L, Gao W. Treatment for liver cancer: From sorafenib to natural products. Eur J Med Chem 2021;224:113690. [PMID: 34256124 DOI: 10.1016/j.ejmech.2021.113690] [Cited by in Crossref: 14] [Cited by in F6Publishing: 19] [Article Influence: 14.0] [Reference Citation Analysis]
18 Rugamba A, Kang DY, Sp N, Jo ES, Lee JM, Bae SW, Jang KJ. Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells. Cells 2021;10:1632. [PMID: 34209829 DOI: 10.3390/cells10071632] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
19 Verdura S, Cuyàs E, Ruiz-Torres V, Micol V, Joven J, Bosch-Barrera J, Menendez JA. Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals (Basel) 2021;14:559. [PMID: 34208282 DOI: 10.3390/ph14060559] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Huo M, Wang H, Li L, Tong Y, Hu C, Gu Y, Liu J, Yin T. Redox-sensitive hyaluronic acid-cholesterol nanovehicles potentiate efficient transmembrane internalization and controlled release for penetrated "full-line" inhibition of pre-metastatic initiation. J Control Release 2021;336:89-104. [PMID: 34119559 DOI: 10.1016/j.jconrel.2021.06.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
21 Velmurugan BK, Lin JT, Mahalakshmi B, Lin CC, Chuang YC, Lo YS, Ho HY, Hsieh MJ, Chen MK. Dehydrocrenatidine inhibits head and neck cancer cells invasion and migration by modulating JNK1/2 and ERK1/2 pathway and decreases MMP-2 expression. Environ Toxicol 2021;36:1848-56. [PMID: 34076342 DOI: 10.1002/tox.23305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Binienda A, Ziolkowska S, Pluciennik E. The Anticancer Properties of Silibinin: Its Molecular Mechanism and Therapeutic Effect in Breast Cancer. Anticancer Agents Med Chem 2020;20:1787-96. [PMID: 31858905 DOI: 10.2174/1871520620666191220142741] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
23 Antal DS, Ardelean F, Avram S, Pavel IZ, Danciu C, Soica C, Dehelean C. Flavonolignans: One Step Further in the Broad-Spectrum Approach of Cancer. Anticancer Agents Med Chem 2020;20:1817-30. [PMID: 31976848 DOI: 10.2174/1871520620666200124112649] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhao TJ, Zhu N, Shi YN, Wang YX, Zhang CJ, Deng CF, Liao DF, Qin L. Targeting HDL in tumor microenvironment: New hope for cancer therapy. J Cell Physiol 2021. [PMID: 34018609 DOI: 10.1002/jcp.30412] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
25 Tolomeo M, Cascio A. The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy. Int J Mol Sci 2021;22:E603. [PMID: 33435349 DOI: 10.3390/ijms22020603] [Cited by in Crossref: 38] [Cited by in F6Publishing: 46] [Article Influence: 38.0] [Reference Citation Analysis]
26 Aziz MA, Sarwar MS, Akter T, Uddin MS, Xun S, Zhu Y, Islam MS, Hongjie Z. Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer. Life Sci 2021;268:118999. [PMID: 33421525 DOI: 10.1016/j.lfs.2020.118999] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
27 Blundell R, Grech JC, Shah MA. Crustacea (Carotenoids Namely Astaxanthins) Against Cancer. Food Bioactive Ingredients 2021. [DOI: 10.1007/978-3-030-74035-1_8] [Reference Citation Analysis]
28 Kaipa JM, Starkuviene V, Erfle H, Eils R, Gladilin E. Transcriptome profiling reveals Silibinin dose-dependent response network in non-small lung cancer cells. PeerJ 2020;8:e10373. [PMID: 33362957 DOI: 10.7717/peerj.10373] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 Mashhadi Akbar Boojar M, Mashhadi Akbar Boojar M, Golmohammad S. Overview of Silibinin anti-tumor effects. Journal of Herbal Medicine 2020;23:100375. [DOI: 10.1016/j.hermed.2020.100375] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
30 Sayed AM, Hassanein EH, Salem SH, Hussein OE, Mahmoud AM. Flavonoids-mediated SIRT1 signaling activation in hepatic disorders. Life Sciences 2020;259:118173. [DOI: 10.1016/j.lfs.2020.118173] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 8.5] [Reference Citation Analysis]
31 Bojňanská T, Vollmannová A, Musilová J. Milk thistle flour effect on dough rheological properties. Potr S J F Sci 2020;14:788-97. [DOI: 10.5219/1365] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
32 Kim C, Hwang JK. Flavonoids: nutraceutical potential for counteracting muscle atrophy. Food Sci Biotechnol 2020;29:1619-40. [PMID: 33282430 DOI: 10.1007/s10068-020-00816-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
33 Liang Y, Zhang T, Zhang J. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy. Pharmacol Res 2020;161:105164. [PMID: 32846211 DOI: 10.1016/j.phrs.2020.105164] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 9.0] [Reference Citation Analysis]
34 Tang J, Wang D, Lu J, Zhou X. MiR-125b participates in the occurrence of preeclampsia by regulating the migration and invasion of extravillous trophoblastic cells through STAT3 signaling pathway. J Recept Signal Transduct Res 2021;41:202-8. [PMID: 32787544 DOI: 10.1080/10799893.2020.1806318] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
35 Liu W, Ji Y, Sun Y, Si L, Fu J, Hayashi T, Onodera S, Ikejima T. Estrogen receptors participate in silibinin-caused nuclear translocation of apoptosis-inducing factor in human breast cancer MCF-7 cells. Archives of Biochemistry and Biophysics 2020;689:108458. [DOI: 10.1016/j.abb.2020.108458] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
36 Yang CY, Tsao CH, Hsieh CC, Lin CK, Lin CS, Li YH, Chang WC, Cheng JC, Lin GJ, Sytwu HK, Wang YL, Chen YW. Downregulation of Jumonji-C domain-containing protein 5 inhibits proliferation by silibinin in the oral cancer PDTX model. PLoS One 2020;15:e0236101. [PMID: 32678829 DOI: 10.1371/journal.pone.0236101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Micale N, Citarella A, Molonia MS, Speciale A, Cimino F, Saija A, Cristani M. Hydrogels for the Delivery of Plant-Derived (Poly)Phenols. Molecules 2020;25:E3254. [PMID: 32708833 DOI: 10.3390/molecules25143254] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
38 Murali Iyangar R, Devaraj E. Silibinin Triggers the Mitochondrial Pathway of Apoptosis in Human Oral Squamous Carcinoma Cells. Asian Pac J Cancer Prev 2020;21:1877-82. [PMID: 32711410 DOI: 10.31557/APJCP.2020.21.7.1877] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
39 Bosch-Barrera J, Martin-Castillo B, Buxó M, Brunet J, Encinar JA, Menendez JA. Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. J Clin Med 2020;9:E1770. [PMID: 32517353 DOI: 10.3390/jcm9061770] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 14.5] [Reference Citation Analysis]
40 Khan H, Belwal T, Efferth T, Farooqi AA, Sanches-Silva A, Vacca RA, Nabavi SF, Khan F, Prasad Devkota H, Barreca D, Sureda A, Tejada S, Dacrema M, Daglia M, Suntar İ, Xu S, Ullah H, Battino M, Giampieri F, Nabavi SM. Targeting epigenetics in cancer: therapeutic potential of flavonoids. Crit Rev Food Sci Nutr 2021;61:1616-39. [PMID: 32478608 DOI: 10.1080/10408398.2020.1763910] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 12.5] [Reference Citation Analysis]
41 Karakurt E, Dağ S. Wistar Ratlarında Dietilnitrozamin Uygulanarak Oluşturulan Hepatoselüler Karsinom Modelinde Silimarin’in Koruyucu Etkisi; Kanser Paternleri ve Sitolojik Varyantlar. Atatürk Üniversitesi Veteriner Bilimleri Dergisi 2020;15:43-50. [DOI: 10.17094/ataunivbd.680945] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Delmas D, Xiao J, Vejux A, Aires V. Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity. Molecules 2020;25:E2009. [PMID: 32344919 DOI: 10.3390/molecules25092009] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
43 You Y, He Q, Lu H, Zhou X, Chen L, Liu H, Lu Z, Liu D, Liu Y, Zuo D, Fu X, Kwan H, Zhao X. Silibinin Induces G2/M Cell Cycle Arrest by Activating Drp1-Dependent Mitochondrial Fission in Cervical Cancer. Front Pharmacol 2020;11:271. [PMID: 32226384 DOI: 10.3389/fphar.2020.00271] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
44 Fan Y, Hou T, Dan W, Liu T, Luan J, Liu B, Li L, Zeng J. Silibinin inhibits epithelial‑mesenchymal transition of renal cell carcinoma through autophagy‑dependent Wnt/β‑catenin signaling. Int J Mol Med 2020;45:1341-50. [PMID: 32323735 DOI: 10.3892/ijmm.2020.4521] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
45 Garro HA, Pungitore CR. DNA Related Enzymes as Molecular Targets for Antiviral and Antitumoral Chemotherapy. A Natural Overview of the Current Perspectives. Curr Drug Targets 2019;20:70-80. [PMID: 29697027 DOI: 10.2174/1389450119666180426103558] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
46 Reznik N, Kozer N, Eisenberg-Lerner A, Barr H, Merbl Y, London N. Phenotypic Screen Identifies JAK2 as a Major Regulator of FAT10 Expression. ACS Chem Biol 2019;14:2538-45. [PMID: 31794190 DOI: 10.1021/acschembio.9b00667] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Cuyàs E, Verdura S, Micol V, Joven J, Bosch-barrera J, Encinar JA, Menendez JA. Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation. Food and Chemical Toxicology 2019;132:110645. [DOI: 10.1016/j.fct.2019.110645] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
48 Chen Q, Lv J, Yang W, Xu B, Wang Z, Yu Z, Wu J, Yang Y, Han Y. Targeted inhibition of STAT3 as a potential treatment strategy for atherosclerosis. Theranostics 2019;9:6424-42. [PMID: 31588227 DOI: 10.7150/thno.35528] [Cited by in Crossref: 51] [Cited by in F6Publishing: 55] [Article Influence: 17.0] [Reference Citation Analysis]
49 Sherman B, Hernandez AM, Alhado M, Menge L, Price RS. Silibinin Differentially Decreases the Aggressive Cancer Phenotype in an In Vitro Model of Obesity and Prostate Cancer. Nutr Cancer 2020;72:333-42. [PMID: 31287731 DOI: 10.1080/01635581.2019.1633363] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
50 Liu Y, Xu W, Zhai T, You J, Chen Y. Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway. Acta Pharm Sin B 2019;9:745-57. [PMID: 31384535 DOI: 10.1016/j.apsb.2019.02.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 17.3] [Reference Citation Analysis]
51 McFarland BC, Benveniste EN. Reactive astrocytes foster brain metastases via STAT3 signaling. Ann Transl Med 2019;7:S83. [PMID: 31576292 DOI: 10.21037/atm.2019.04.17] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
52 Pérez-Sánchez A, Cuyàs E, Ruiz-Torres V, Agulló-Chazarra L, Verdura S, González-Álvarez I, Bermejo M, Joven J, Micol V, Bosch-Barrera J, Menendez JA. Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. Int J Mol Sci 2019;20:E1606. [PMID: 30935093 DOI: 10.3390/ijms20071606] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
53 Zheng H, Yang L, Kang Y, Chen M, Lin S, Xiang Y, Li C, Dai X, Huang X, Liang G, Zhao C. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling. Molecular Carcinogenesis 2019;58:565-76. [DOI: 10.1002/mc.22951] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 10.3] [Reference Citation Analysis]
54 Shi Z, Zhou Q, Gao S, Li W, Li X, Liu Z, Jin P, Jiang J. Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation. Life Sciences 2019;217:70-80. [DOI: 10.1016/j.lfs.2018.11.037] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 8.3] [Reference Citation Analysis]
55 Ullah MF, Bhat SH, Abu-duhier FM. Nutraceuticals and Natural Product Derivatives in the Premises of Disease Prevention. Nutraceuticals and Natural Product Derivatives 2018. [DOI: 10.1002/9781119436713.ch5] [Reference Citation Analysis]
56 Jahanafrooz Z, Motamed N, Rinner B, Mokhtarzadeh A, Baradaran B. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci 2018;213:236-47. [PMID: 30308184 DOI: 10.1016/j.lfs.2018.10.009] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 11.0] [Reference Citation Analysis]
57 Liu Y, Yu Q, Chen Y. Effect of silibinin on CFLAR-JNK pathway in oleic acid-treated HepG2 cells.Biomed Pharmacother. 2018;108:716-723. [PMID: 30248539 DOI: 10.1016/j.biopha.2018.09.089] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
58 Chiou Y, Li S, Ho C, Pan M. Prevention of Breast Cancer by Natural Phytochemicals: Focusing on Molecular Targets and Combinational Strategy. Mol Nutr Food Res 2018;62:1800392. [DOI: 10.1002/mnfr.201800392] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
59 Yao M, Rogers L, Suchowerska N, Choe D, Al-Dabbas MA, Narula RS, Lyons JG, Sved P, Li Z, Dong Q. Sensitization of prostate cancer to radiation therapy: Molecules and pathways to target. Radiother Oncol 2018;128:283-300. [PMID: 29929859 DOI: 10.1016/j.radonc.2018.05.021] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
60 Wang N, He X, Zhou R, Jia G, Qiao Q. STAT3 induces colorectal carcinoma progression through a novel miR-572-MOAP-1 pathway. Onco Targets Ther. 2018;11:3475-3484. [PMID: 29942139 DOI: 10.2147/ott.s158764] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
61 Priego N, Zhu L, Monteiro C, Mulders M, Wasilewski D, Bindeman W, Doglio L, Martínez L, Martínez-Saez E, Ramón Y Cajal S, Megías D, Hernández-Encinas E, Blanco-Aparicio C, Martínez L, Zarzuela E, Muñoz J, Fustero-Torre C, Piñeiro-Yáñez E, Hernández-Laín A, Bertero L, Poli V, Sanchez-Martinez M, Menendez JA, Soffietti R, Bosch-Barrera J, Valiente M. STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nat Med 2018;24:1024-35. [PMID: 29892069 DOI: 10.1038/s41591-018-0044-4] [Cited by in Crossref: 171] [Cited by in F6Publishing: 186] [Article Influence: 42.8] [Reference Citation Analysis]
62 Verdura S, Cuyàs E, Llorach-Parés L, Pérez-Sánchez A, Micol V, Nonell-Canals A, Joven J, Valiente M, Sánchez-Martínez M, Bosch-Barrera J, Menendez JA. Silibinin is a direct inhibitor of STAT3. Food Chem Toxicol 2018;116:161-72. [PMID: 29660364 DOI: 10.1016/j.fct.2018.04.028] [Cited by in Crossref: 40] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
63 Han L, Guo K, Gu F, Zhang YF, Li K, Mu XX, Liu HJ, Zhou XD, Luo W. Effects of silibinin-loaded thermosensitive liposome-microbubble complex on inhibiting rabbit liver VX2 tumors in sub-hyperthermia fields. Exp Ther Med 2018;15:1233-40. [PMID: 29434709 DOI: 10.3892/etm.2017.5566] [Reference Citation Analysis]
64 Hou X, Du H, Quan X, Shi L, Zhang Q, Wu Y, Liu Y, Xiao J, Li Y, Lu L, Ai X, Zhan M, Yuan S, Sun L. Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway. Front Pharmacol 2018;9:21. [PMID: 29472856 DOI: 10.3389/fphar.2018.00021] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
65 Zhang L, Qi M, Feng T, Hu J, Wang L, Li X, Gao W, Liu H, Jiao M, Wu Z, Bai X, Bie Y, Liu L, Han B. IDH1R132H Promotes Malignant Transformation of Benign Prostatic Epithelium by Dysregulating MicroRNAs: Involvement of IGF1R-AKT/STAT3 Signaling Pathway. Neoplasia 2018;20:207-17. [PMID: 29331887 DOI: 10.1016/j.neo.2017.12.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
66 Bosch-Barrera J, Sais E, Cañete N, Marruecos J, Cuyàs E, Izquierdo A, Porta R, Haro M, Brunet J, Pedraza S, Menendez JA. Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget 2016;7:32006-14. [PMID: 26959886 DOI: 10.18632/oncotarget.7900] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 6.2] [Reference Citation Analysis]
67 Amani H, Ajami M, Nasseri Maleki S, Pazoki-toroudi H, Daglia M, Tsetegho Sokeng AJ, Di Lorenzo A, Nabavi SF, Devi KP, Nabavi SM. Targeting signal transducers and activators of transcription (STAT) in human cancer by dietary polyphenolic antioxidants. Biochimie 2017;142:63-79. [DOI: 10.1016/j.biochi.2017.08.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
68 Bhatia S, Monkman J, Toh AKL, Nagaraj SH, Thompson EW. Targeting epithelial-mesenchymal plasticity in cancer: clinical and preclinical advances in therapy and monitoring. Biochem J 2017;474:3269-306. [PMID: 28931648 DOI: 10.1042/BCJ20160782] [Cited by in Crossref: 45] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
69 Baeeri M, Mohammadi-Nejad S, Rahimifard M, Navaei-Nigjeh M, Moeini-Nodeh S, Khorasani R, Abdollahi M. Molecular and biochemical evidence on the protective role of ellagic acid and silybin against oxidative stress-induced cellular aging. Mol Cell Biochem 2018;441:21-33. [PMID: 28887692 DOI: 10.1007/s11010-017-3172-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
70 Zou H, Zhu XX, Zhang GB, Ma Y, Wu Y, Huang DS. Silibinin: an old drug for hematological disorders. Oncotarget 2017;8:89307-14. [PMID: 29179521 DOI: 10.18632/oncotarget.19153] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
71 Bosch-barrera J, Queralt B, Menendez JA. Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treatment Reviews 2017;58:61-9. [DOI: 10.1016/j.ctrv.2017.06.003] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 11.8] [Reference Citation Analysis]
72 Wang J, Guo XJ, Ding YM, Jiang JX. miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. World J Gastroenterol 2017; 23(9): 1594-1601 [PMID: 28321160 DOI: 10.3748/wjg.v23.i9.1594] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
73 Molavi O, Narimani F, Asiaee F, Sharifi S, Tarhriz V, Shayanfar A, Hejazi M, Lai R. Silibinin sensitizes chemo-resistant breast cancer cells to chemotherapy. Pharm Biol 2017;55:729-39. [PMID: 28027688 DOI: 10.1080/13880209.2016.1270972] [Cited by in Crossref: 45] [Cited by in F6Publishing: 37] [Article Influence: 9.0] [Reference Citation Analysis]
74 Stolf AM, Cardoso CC, Acco A. Effects of Silymarin on Diabetes Mellitus Complications: A Review. Phytother Res 2017;31:366-74. [PMID: 28124457 DOI: 10.1002/ptr.5768] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 9.4] [Reference Citation Analysis]
75 Lakkim V, Reddy MC, Prasad DVR, Lomada D. Role of STAT3 in Colorectal Cancer Development. Role of Transcription Factors in Gastrointestinal Malignancies 2017. [DOI: 10.1007/978-981-10-6728-0_19] [Cited by in Crossref: 4] [Article Influence: 0.8] [Reference Citation Analysis]
76 Anestopoulos I, Sfakianos AP, Franco R, Chlichlia K, Panayiotidis MI, Kroll DJ, Pappa A. A Novel Role of Silibinin as a Putative Epigenetic Modulator in Human Prostate Carcinoma. Molecules 2016;22:E62. [PMID: 28042859 DOI: 10.3390/molecules22010062] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
77 Momtaz S, Niaz K, Maqbool F, Abdollahi M, Rastrelli L, Nabavi SM. STAT3 targeting by polyphenols: Novel therapeutic strategy for melanoma: STAT3 targeting by polyphenols. BioFactors 2017;43:347-70. [DOI: 10.1002/biof.1345] [Cited by in Crossref: 25] [Cited by in F6Publishing: 29] [Article Influence: 4.2] [Reference Citation Analysis]
78 Gorges TM, Kuske A, Röck K, Mauermann O, Müller V, Peine S, Verpoort K, Novosadova V, Kubista M, Riethdorf S, Pantel K. Accession of Tumor Heterogeneity by Multiplex Transcriptome Profiling of Single Circulating Tumor Cells. Clinical Chemistry 2016;62:1504-15. [DOI: 10.1373/clinchem.2016.260299] [Cited by in Crossref: 102] [Cited by in F6Publishing: 107] [Article Influence: 17.0] [Reference Citation Analysis]
79 Jiang C, Jin S, Jiang Z, Wang J. Inhibitory effects of silibinin on proliferation and lung metastasis of human high metastasis cell line of salivary gland adenoid cystic carcinoma via autophagy induction. Onco Targets Ther 2016;9:6609-18. [PMID: 27822066 DOI: 10.2147/OTT.S107101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
80 Cuyàs E, Pérez-Sánchez A, Micol V, Menendez JA, Bosch-Barrera J. STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. Cell Cycle 2016;15:3413-8. [PMID: 27753543 DOI: 10.1080/15384101.2016.1245249] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 5.8] [Reference Citation Analysis]
81 Shukla SK, Dasgupta A, Mehla K, Gunda V, Vernucci E, Souchek J, Goode G, King R, Mishra A, Rai I. Silibinin-mediated metabolic reprogramming attenuates pancreatic cancer-induced cachexia and tumor growth. Oncotarget. 2015;6:41146-41161. [PMID: 26510913 DOI: 10.18632/oncotarget.5843] [Cited by in Crossref: 52] [Cited by in F6Publishing: 56] [Article Influence: 8.7] [Reference Citation Analysis]
82 Abdal Dayem A, Choi HY, Yang GM, Kim K, Saha SK, Cho SG. The Anti-Cancer Effect of Polyphenols against Breast Cancer and Cancer Stem Cells: Molecular Mechanisms. Nutrients 2016;8:E581. [PMID: 27657126 DOI: 10.3390/nu8090581] [Cited by in Crossref: 92] [Cited by in F6Publishing: 98] [Article Influence: 15.3] [Reference Citation Analysis]
83 Singh M, Garg N, Venugopal C, Hallett R, Tokar T, McFarlane N, Mahendram S, Bakhshinyan D, Manoranjan B, Vora P, Qazi M, Arpin CC, Page B, Haftchenary S, Rosa DA, Lai PS, Gómez-Biagi RF, Ali AM, Lewis A, Geletu M, Murty NK, Hassell JA, Jurisica I, Gunning PT, Singh SK. STAT3 pathway regulates lung-derived brain metastasis initiating cell capacity through miR-21 activation. Oncotarget 2015;6:27461-77. [PMID: 26314961 DOI: 10.18632/oncotarget.4742] [Cited by in Crossref: 32] [Cited by in F6Publishing: 39] [Article Influence: 5.3] [Reference Citation Analysis]
84 Liang M, Zhan F, Zhao J, Li Q, Wuyang J, Mu G, Li D, Zhang Y, Huang X. CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3. BMC Cancer 2016;16:504. [PMID: 27435207 DOI: 10.1186/s12885-016-2488-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
85 Zhu XX, Ding YH, Wu Y, Qian LY, Zou H, He Q. Silibinin: a potential old drug for cancer therapy. Expert Rev Clin Pharmacol. 2016; 18: 1-8 Epub ahead of print. [PMID: 27362364 DOI: 10.1080/17512433.2016.1208563] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
86 Badhani B, Kakkar R. In silico studies on potential MCF-7 inhibitors: a combination of pharmacophore and 3D-QSAR modeling, virtual screening, molecular docking, and pharmacokinetic analysis. J Biomol Struct Dyn 2017;35:1950-67. [PMID: 27401212 DOI: 10.1080/07391102.2016.1202863] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
87 Sbiera S, Deutschbein T, Weigand I, Reincke M, Fassnacht M, Allolio B. The New Molecular Landscape of Cushing's Disease. Trends Endocrinol Metab 2015;26:573-83. [PMID: 26412158 DOI: 10.1016/j.tem.2015.08.003] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.8] [Reference Citation Analysis]
88 Aichem A, Groettrup M. The ubiquitin-like modifier FAT10 in cancer development. Int J Biochem Cell Biol. 2016;79:451-461. [PMID: 27393295 DOI: 10.1016/j.biocel.2016.07.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 7.3] [Reference Citation Analysis]
89 Jiang S, Gao Y, Hou W, Liu R, Qi X, Xu X, Li J, Bao Y, Zheng H, Hua B. Sinomenine inhibits A549 human lung cancer cell invasion by mediating the STAT3 signaling pathway. Oncol Lett 2016;12:1380-6. [PMID: 27446441 DOI: 10.3892/ol.2016.4768] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
90 Chen SR, Qiu HC, Hu Y, Wang Y, Wang YT. Herbal Medicine Offered as an Initiative Therapeutic Option for the Management of Hepatocellular Carcinoma. Phytother Res 2016;30:863-77. [PMID: 26879574 DOI: 10.1002/ptr.5594] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
91 Yuan J, Zhang F, Niu R. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci Rep 2015;5:17663. [PMID: 26631279 DOI: 10.1038/srep17663] [Cited by in Crossref: 130] [Cited by in F6Publishing: 154] [Article Influence: 18.6] [Reference Citation Analysis]
92 Zhao C, Li H, Lin HJ, Yang S, Lin J, Liang G. Feedback Activation of STAT3 as a Cancer Drug-Resistance Mechanism. Trends Pharmacol Sci. 2016;37:47-61. [PMID: 26576830 DOI: 10.1016/j.tips.2015.10.001] [Cited by in Crossref: 125] [Cited by in F6Publishing: 145] [Article Influence: 17.9] [Reference Citation Analysis]
93 Ben Rahal N, Barba FJ, Barth D, Chevalot I. Supercritical CO2 extraction of oil, fatty acids and flavonolignans from milk thistle seeds: Evaluation of their antioxidant and cytotoxic activities in Caco-2 cells. Food and Chemical Toxicology 2015;83:275-82. [DOI: 10.1016/j.fct.2015.07.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 5.1] [Reference Citation Analysis]
94 Zhang L, Wang H. Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin. Mar Drugs 2015;13:4310-30. [PMID: 26184238 DOI: 10.3390/md13074310] [Cited by in Crossref: 111] [Cited by in F6Publishing: 114] [Article Influence: 15.9] [Reference Citation Analysis]